Robert Flavell, MD, PhD
Diagnostic Radiology • Nuclear MedicineChief, Molecular Imaging and Therapeutics
Robert Flavell, MD, PhD
Diagnostic Radiology • Nuclear MedicineChief, Molecular Imaging and TherapeuticsOn this page
About me
Dr. Robert Flavell is a radiologist who cares for both adults and children, and specializes in nuclear medicine, the use of small amounts of radioactive materials to evaluate organ systems. He is chief of molecular imaging and therapeutics for the UCSF Department of Radiology and Biomedical Imaging.
In research, Flavell focuses on developing new methods of diagnosing and treating cancer using molecular imaging technology, which shows what is taking place in the body at a cellular and molecular level.
After earning a doctorate in chemical biology at the Rockefeller University, Flavell earned his medical degree at Weill Cornell Medicine. At UCSF, he completed a residency in diagnostic radiology, followed by a fellowship in nuclear medicine.
Education & training
Board certification
- Nuclear Medicine, American Board of Nuclear Medicine
- Diagnostic Radiology, American Board of Radiology
Fellowship
- Nuclear Medicine, UCSF Graduate Medical Education
Residency
- Diagnostic Radiology, UCSF Graduate Medical Education
Internship
- Transitional, Memorial Sloan-Kettering Cancer Center (GME)
Degree
- MD, Weill Cornell Graduate School of Medical Sciences
My expertise
Specialties
- Diagnostic Radiology
- Nuclear Medicine
Locations
Clinical Trials query: q=health_gateway_id_ss%3A%28%221855%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%221855%22%29&rows=4&sort=date_published+desc&fq=content_type%3A%22Publication%22
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.